



Clinical trial results:

A Phase IIIb observer-blind, randomized, multicentre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine and Merck's Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, when administered intramuscularly according to alternative 2-dose schedules in 9-14 year old healthy females.

Summary

| | |
|--------------------------|-----------------|
| EudraCT number | 2011-002035-26 |
| Trial protocol | FR SE |
| Global end of trial date | 27 October 2015 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 |
| This version publication date | 21 April 2016 |
| First version publication date | 21 April 2016 |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 115411 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01462357 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | GlaxoSmithKline Biologicals |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330 |
| Public contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com |

Notes:

Paediatric regulatory details

| | |
|--|-----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

Results analysis stage

| | |
|--|-----------------|
| Analysis stage | Interim |
| Date of interim/final analysis | 01 April 2016 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 27 October 2015 |
| Global end of trial reached? | Yes |
| Global end of trial date | 27 October 2015 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To evaluate sequentially if the immunogenicity (as determined by enzyme-linked immunosorbent assay - ELISA) of GSK Biologicals' HPV-16/18 L1 Virus-like-particle (VLP) AS04 vaccine administered according to a 2-dose schedule at 0, 6 months is non-inferior/superior to that of Merck's HPV-6/11/16/18 L1 VLP recombinant vaccine administered according to a 2- dose schedule at 0, 6 months in 9-14 years old females, 1 month after the last dose (Month 7).

Protection of trial subjects:

All subjects were supervised for 30 min after vaccination/product administration with appropriate medical treatment readily available. Vaccines/products were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines/products. Subjects were followed-up for 30 days after the last vaccination/product administration.

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 21 November 2011 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|----------------|
| Country: Number of subjects enrolled | Sweden: 72 |
| Country: Number of subjects enrolled | France: 231 |
| Country: Number of subjects enrolled | Hong Kong: 534 |
| Country: Number of subjects enrolled | Singapore: 242 |
| Worldwide total number of subjects | 1079 |
| EEA total number of subjects | 303 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 | 0 |

| | |
|---------------------------|-----|
| months) | |
| Children (2-11 years) | 539 |
| Adolescents (12-17 years) | 540 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

1079 subjects entered this study, of which 4 subjects signed an informed consent but did not receive a single dose of the vaccine and were hence not counted as starting the study.

Pre-assignment period milestones

| | |
|------------------------------|------|
| Number of subjects started | 1079 |
| Number of subjects completed | 1075 |

Pre-assignment subject non-completion reasons

| | |
|----------------------------|----------------------------|
| Reason: Number of subjects | No vaccine administered: 4 |
|----------------------------|----------------------------|

Period 1

| | |
|------------------------------|---------------------------------|
| Period 1 title | Overall Period (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Assessor |

Blinding implementation details:

Data was collected in an observer-blind manner. By observer-blind, it is meant that during the course of the study, the vaccine recipient and those responsible for the evaluation of any study endpoint (e.g. immunogenicity, reactogenicity, and safety) were all unaware of which vaccine was administered. To do so, vaccine preparation and administration were be done by authorised medical personnel who did not participate in any of the study clinical evaluation assays.

Arms

| | |
|------------------------------|-----------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Cervarix 2 dose Group |

Arm description:

Subjects who received 2 doses of Cervarix™ vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Cervarix™ |
| Investigational medicinal product code | |
| Other name | HPV 1 |
| Pharmaceutical forms | Suspension for injection in pre-filled syringe |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 2 doses of Cervarix™ Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.

| | |
|--|--|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection in pre-filled syringe |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 1 dose of 0.5 mL supplied as a liquid in individual pre-filled syringes, administered

intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding.

| | |
|------------------|-----------------------|
| Arm title | Gardasil 2 dose Group |
|------------------|-----------------------|

Arm description:

Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Gardasil® |
| Investigational medicinal product code | |
| Other name | HPV 2 |
| Pharmaceutical forms | Suspension for injection in pre-filled syringe |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.

| | |
|--|--|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection in pre-filled syringe |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 1 dose of 0.5 mL supplied as a liquid in individual pre-filled syringes, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding.

| | |
|------------------|-----------------------|
| Arm title | Gardasil 3 dose Group |
|------------------|-----------------------|

Arm description:

Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Gardasil® |
| Investigational medicinal product code | |
| Other name | HPV 2 |
| Pharmaceutical forms | Suspension for injection in pre-filled syringe |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 3 doses of Gardasil® vaccine at Day 0, Month 2 and Month 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.

| Number of subjects in period 1^[1] | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group |
|---|-----------------------|-----------------------|-----------------------|
| Started | 359 | 358 | 358 |
| Completed at Month 7 | 358 | 353 | 352 |
| Completed at Month 12 | 356 | 348 | 350 |
| Completed at Month 18 | 356 | 347 | 349 |
| Completed at Month 24 | 355 | 344 | 349 |

| | | | |
|--------------------------------|-----|-----|-----|
| Completed | 355 | 344 | 349 |
| Not completed | 4 | 14 | 9 |
| Consent withdrawn by subject | 2 | 8 | 3 |
| Migrated/moved from study area | - | 2 | - |
| Lost to follow-up | 2 | 4 | 6 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 1079 subjects entered this study, of which 4 subjects signed an informed consent but did not receive a single dose of the vaccine and were hence not counted as starting the study.

Baseline characteristics

Reporting groups

| | |
|-----------------------|-----------------------|
| Reporting group title | Cervarix 2 dose Group |
|-----------------------|-----------------------|

Reporting group description:

Subjects who received 2 doses of Cervarix™ vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.

| | |
|-----------------------|-----------------------|
| Reporting group title | Gardasil 2 dose Group |
|-----------------------|-----------------------|

Reporting group description:

Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.

| | |
|-----------------------|-----------------------|
| Reporting group title | Gardasil 3 dose Group |
|-----------------------|-----------------------|

Reporting group description:

Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.

| Reporting group values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group |
|---|-----------------------|-----------------------|-----------------------|
| Number of subjects | 359 | 358 | 358 |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |
| Age continuous Units: years | | | |
| arithmetic mean | 11.5 | 11.5 | 11.6 |
| standard deviation | ± 1.64 | ± 1.56 | ± 1.64 |
| Gender categorical Units: Subjects | | | |
| Female | 359 | 358 | 358 |
| Male | 0 | 0 | 0 |

| Reporting group values | Total | | |
|--|-------|--|--|
| Number of subjects | 1075 | | |
| Age categorical Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |

| | | | |
|---|------|--|--|
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 0 | | |
| Adults (18-64 years) | 0 | | |
| From 65-84 years | 0 | | |
| 85 years and over | 0 | | |
| Age continuous Units: years arithmetic mean standard deviation | - | | |
| Gender categorical Units: Subjects | | | |
| Female | 1075 | | |
| Male | 0 | | |

End points

End points reporting groups

| | |
|--|-----------------------|
| Reporting group title | Cervarix 2 dose Group |
| Reporting group description: Subjects who received 2 doses of Cervarix™ vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm. | |
| Reporting group title | Gardasil 2 dose Group |
| Reporting group description: Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm. | |
| Reporting group title | Gardasil 3 dose Group |
| Reporting group description: Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm. | |

Primary: Number of seroconverted subjects for Anti-HPV-16/18, as assessed by the enzyme-immunosorbent assay (ELISA)

| | |
|--|--|
| End point title | Number of seroconverted subjects for Anti-HPV-16/18, as assessed by the enzyme-immunosorbent assay (ELISA) |
| End point description: Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 19 and 18 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study. | |
| End point type | Primary |
| End point timeframe: One month after the last dose of study vaccine (Month 7) | |

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|-----------------------------|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 337 | 334 | 334 | |
| Units: Subjects | | | | |
| Anti-HPV-16 (N=337,334,334) | 337 | 334 | 334 | |
| Anti-HPV-18 (N=337,334,334) | 337 | 334 | 334 | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Immune response to anti-HPV-16 in terms of SCR |
| Statistical analysis description: To evaluate sequentially if the immunogenicity (as determined by enzyme-linked immunosorbent assay - ELISA) of the Cervarix™ vaccine administered according to a 2-dose schedule at 0, 6 months is non-inferior to that of the Gardasil® vaccine administered according to a 2- dose schedule at 0, 6 months in 9-14 years old females, 1 month after the last dose (Month 7). | |

| | |
|---|---|
| Comparison groups | Cervarix 2 dose Group v Gardasil 2 dose Group |
| Number of subjects included in analysis | 671 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[1] |
| Parameter estimate | Difference in SCR |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.16 |
| upper limit | 1.15 |

Notes:

[1] - Non-inferiority with respect to seroconversion will be shown if, at Months 12, 18, 24 and 36, for both anti-HPV-16 and anti-HPV-18 antibodies, the upper limit of the 95% confidence interval (CI) for the difference (Gardasil 2 dose Group - Cervarix 2 dose Group) is below 5%.

| | |
|-----------------------------------|--|
| Statistical analysis title | Immune response to anti-HPV-18 in terms of SCR |
|-----------------------------------|--|

Statistical analysis description:

To evaluate sequentially if the immunogenicity (as determined by enzyme-linked immunosorbent assay - ELISA) of the Cervarix™ vaccine administered according to a 2-dose schedule at 0, 6 months is non-inferior to that of the Gardasil® vaccine administered according to a 2- dose schedule at 0, 6 months in 9-14 years old females, 1 month after the last dose (Month 7).

| | |
|---|---|
| Comparison groups | Cervarix 2 dose Group v Gardasil 2 dose Group |
| Number of subjects included in analysis | 671 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[2] |
| Parameter estimate | Difference in SCR |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.15 |
| upper limit | 1.14 |

Notes:

[2] - Non-inferiority with respect to seroconversion will be shown if, at Months 12, 18, 24 and 36, for both anti-HPV-16 and anti-HPV-18 antibodies, the upper limit of the 95% confidence interval (CI) for the difference (Gardasil 2 dose Group - Cervarix 2 dose Group) is below 5%.

Primary: Anti-HPV-16/18 antibody concentrations assessed by ELISA

| | |
|-----------------|--|
| End point title | Anti-HPV-16/18 antibody concentrations assessed by ELISA |
|-----------------|--|

End point description:

Anti-HPV 16/18 antibody concentrations were presented as geometric mean concentration (GMC) and expressed in ELISA units per milliliter (EL.U/mL) based on an enzyme-linked immunosorbent assay (ELISA).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

One month after the last dose of study vaccine (Month 7)

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|--|---------------------------|-------------------------|---------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 337 | 334 | 334 | |
| Units: EL.U/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-HPV-16 (N=337,334,334) | 8311.4 (7745.8 to 8918.3) | 5061 (4604.1 to 5563.3) | 4864 (4481.9 to 5278.7) | |
| Anti-HPV-18 (N=337,334,334) | 5249.7 (4835.4 to 5699.5) | 1213 (1098 to 1339.1) | 1654.5 (1485.8 to 1842.4) | |

Statistical analyses

| Statistical analysis title | Immune response to anti-HPV-16 in terms of GMT |
|--|--|
| Statistical analysis description: | |
| To evaluate sequentially if the immunogenicity (as determined by enzyme-linked immunosorbent assay - ELISA) of the Cervarix™ vaccine administered according to a 2-dose schedule at 0, 6 months is non-inferior to that of the Gardasil® vaccine administered according to a 2- dose schedule at 0, 6 months in 9-14 years old females, 1 month after the last dose (Month 7). | |
| Comparison groups | Cervarix 2 dose Group v Gardasil 2 dose Group |
| Number of subjects included in analysis | 671 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[3] |
| Method | ANOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 0.61 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.54 |
| upper limit | 0.69 |

Notes:

[3] - Non-inferiority with respect to GMT will be shown if, at Months 12, 18, 24 and 36, for both anti-HPV-16 and anti-HPV-18 antibodies, the upper limit of the 95% confidence interval (CI) for the GMT ratio (Gardasil 2 dose Group/Cervarix 2 dose Group) is below 2.

| Statistical analysis title | Immune response to anti-HPV-18 in terms of GMT |
|--|--|
| Statistical analysis description: | |
| To evaluate sequentially if the immunogenicity (as determined by enzyme-linked immunosorbent assay - ELISA) of the Cervarix™ vaccine administered according to a 2-dose schedule at 0, 6 months is non-inferior to that of the Gardasil® vaccine administered according to a 2- dose schedule at 0, 6 months in 9-14 years old females, 1 month after the last dose (Month 7). | |
| Comparison groups | Cervarix 2 dose Group v Gardasil 2 dose Group |
| Number of subjects included in analysis | 671 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[4] |
| Method | ANOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 0.23 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.2 |
| upper limit | 0.26 |

Notes:

[4] - Non-inferiority with respect to GMT will be shown if, at Months 12, 18, 24 and 36, for both anti-HPV-16 and anti-HPV-18 antibodies, the upper limit of the 95% confidence interval (CI) for the GMT ratio (Gardasil 2 dose Group/Cervarix 2 dose Group) is below 2.

| | |
|-----------------------------------|-----------------------------|
| Statistical analysis title | Anti-HPV-18 immune response |
|-----------------------------------|-----------------------------|

Statistical analysis description:

To evaluate sequentially if the immunogenicity (as determined by enzyme-linked immunosorbent assay - ELISA) of the Cervarix™ vaccine administered according to a 2-dose schedule at 0, 6 months is superior to that of the Gardasil® vaccine administered according to a 2- dose schedule at 0, 6 months in 9-14 years old females, 1 month after the last dose (Month 7).

| | |
|---|---|
| Comparison groups | Cervarix 2 dose Group v Gardasil 2 dose Group |
| Number of subjects included in analysis | 671 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[5] |
| Method | ANOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 4.52 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 3.97 |
| upper limit | 5.13 |

Notes:

[5] - Superiority will be shown if the lower limit of the 95% confidence interval (CI) for the ratio of geometric mean titers (GMTs) (Cervarix 2 dose Group divided by Gardasil 2 dose Group) is above 1 for anti-HPV-18 antibodies with the associated p-value.

| | |
|-----------------------------------|-----------------------------|
| Statistical analysis title | Anti-HPV-16 immune response |
|-----------------------------------|-----------------------------|

Statistical analysis description:

To evaluate sequentially if the immunogenicity (as determined by enzyme-linked immunosorbent assay - ELISA) of the Cervarix™ vaccine administered according to a 2-dose schedule at 0, 6 months is superior to that of the Gardasil® vaccine administered according to a 2- dose schedule at 0, 6 months in 9-14 years old females, 1 month after the last dose (Month 7).

| | |
|---|---|
| Comparison groups | Cervarix 2 dose Group v Gardasil 2 dose Group |
| Number of subjects included in analysis | 671 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[6] |
| Method | ANOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.69 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.49 |
| upper limit | 1.91 |

Notes:

[6] - Superiority will be shown if the lower limit of the 95% confidence interval (CI) for the ratio of geometric mean titers (GMTs) (Cervarix 2 dose Group divided by Gardasil 2 dose Group) is above 1 for anti-HPV-16 antibodies with the associated p-value.

Secondary: Anti-HPV-16/18 number of subjects with geometreic mean concentrations (GMCs) above 18 ELISA units per milliliter (EU/mL)

| | |
|-----------------|--|
| End point title | Anti-HPV-16/18 number of subjects with geometreic mean concentrations (GMCs) above 18 ELISA units per milliliter (EU/mL) |
|-----------------|--|

End point description:

At the time of posting this record, the results for Month 36 were not available. The record will be updated when the additional validated results are available.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 0 and Months 12, 18, 24 and 36

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|---------------------------------------|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 337 | 334 | 334 | |
| Units: Subjects | | | | |
| Anti-HPV-16, Day 0 (N=337,334,334) | 7 | 7 | 12 | |
| Anti-HPV-18, Day 0 (N=337,334,334) | 3 | 3 | 1 | |
| Anti-HPV-16, Month 12 (N=331,325,327) | 330 | 325 | 327 | |
| Anti-HPV-18, Month 12 (N=331,325,327) | 330 | 324 | 327 | |
| Anti-HPV-16, Month 18 (N=329,327,330) | 329 | 326 | 330 | |
| Anti-HPV-18, Month 18 (N=329,327,330) | 329 | 310 | 322 | |
| Anti-HPV-16, Month 24 (N=324,320,324) | 324 | 319 | 324 | |
| Anti-HPV-18, Month 24 (N=324,320,324) | 324 | 298 | 313 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-HPV-16/18 antibody concentrations assessed by ELISA

| | |
|-----------------|--|
| End point title | Anti-HPV-16/18 antibody concentrations assessed by ELISA |
|-----------------|--|

End point description:

Anti-HPV 16/18 antibody concentrations were presented as geometric mean concentration (GMC) and expressed in ELISA units per milliliter (EL.U/mL) based on an enzyme-linked immunosorbent assay (ELISA). At the time of posting this record, the results for Month 36 were not available. The record will be updated when the additional validated results are available.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 0 and Months 12, 18, 24 and 36

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|--|---------------------------|---------------------------|---------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 337 | 334 | 334 | |
| Units: EL.U/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-HPV-16, Day 0 (N=337,334,334) | 9.8 (9.5 to 10.2) | 9.8 (9.5 to 10.1) | 10 (9.7 to 10.3) | |
| Anti-HPV-18, Day 0 (N=337,334,334) | 9.1 (9 to 9.2) | 9.1 (9 to 9.2) | 9 (9 to 9.1) | |
| Anti-HPV-16, Month 12 (N=331,325,327) | 2247.9 (2052.2 to 2462.2) | 1283.9 (1152.1 to 1430.8) | 1610.5 (1468.9 to 1765.8) | |
| Anti-HPV-18, Month 12 (N=331,325,327) | 1311.4 (1187.3 to 1448.4) | 266 (236.2 to 299.4) | 477.8 (422.7 to 540.1) | |
| Anti-HPV-16, Month 18 (N=329,327,330) | 1516.2 (1393.4 to 1649.8) | 675.8 (600 to 761.1) | 828 (749.8 to 914.4) | |
| Anti-HPV-18, Month 18 (N=329,327,330) | 763.1 (691.3 to 842.5) | 133.8 (117.6 to 152.1) | 230.8 (202.1 to 263.6) | |
| Anti-HPV-16, Month 24 (N=324,320,324) | 1317.5 (1213.9 to 1430) | 514.4 (456.9 to 579.2) | 639.9 (579.6 to 706.6) | |
| Anti-HPV-18, Month 24 (N=324,317,324) | 628.6 (569.4 to 694) | 107.8 (94.8 to 122.6) | 182.2 (159.6 to 208) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-HPV-16/18 seroconversion rates assessed by pseudovirion-based neutralization assay (PBNA) in a subset of subjects

| | |
|------------------------|--|
| End point title | Anti-HPV-16/18 seroconversion rates assessed by pseudovirion-based neutralization assay (PBNA) in a subset of subjects |
| End point description: | Anti-HPV-16/18 seroconversion rates assessed by pseudovirion-based neutralization assay (PBNA) in a subset of subjects |
| End point type | Secondary |
| End point timeframe: | At Day 0 and Months 7, 12, 18, 24 and 36 |

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|-----------------------------------|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 92 | 95 | 93 | |
| Units: Subjects | | | | |
| Anti-HPV-16, Day 0 (N=92,94,93) | 0 | 1 | 0 | |
| Anti-HPV-18, Day 0 (N=92,95,93) | 0 | 0 | 0 | |
| Anti-HPV-16, Month 7 (N=92,94,93) | 92 | 95 | 93 | |
| Anti-HPV-18, Month 7 (N=92,95,93) | 92 | 95 | 93 | |

| | | | | |
|------------------------------------|----|----|----|--|
| Anti-HPV-16, Month 12 (N=90,91,91) | 90 | 93 | 91 | |
| Anti-HPV-18, Month 12 (N=90,93,91) | 90 | 91 | 91 | |
| Anti-HPV-16, Month 18 (N=90,90,91) | 90 | 89 | 90 | |
| Anti-HPV-18, Month 18 (N=89,92,92) | 89 | 81 | 90 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-HPV-16/18 antibody titers assessed by PBNA in a subset of subjects

| | |
|-----------------|---|
| End point title | Anti-HPV-16/18 antibody titers assessed by PBNA in a subset of subjects |
|-----------------|---|

End point description:

Anti-HPV 16/18 antibody titers were presented as geometric mean titers (GMT) and expressed in titers using the pseudovirion-based neutralization assay (PNBA). At the time of posting this record, the results for Months 24 and 36 were not available. The record will be updated when the additional validated results are

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 0 and Months 7, 12, 18, 24 and 36

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|--|---------------------------------|-------------------------------|---------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 92 | 95 | 93 | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-HPV-16, Day 0 (N=92,95,93) | 20 (20 to 20) | 20.2 (19.8 to 20.5) | 20 (20 to 20) | |
| Anti-HPV-18, Day 0 (N=92,95,93) | 20 (20 to 20) | 20 (20 to 20) | 20 (20 to 20) | |
| Anti-HPV-16, Month 7 (N=92,95,93) | 51043.8 (42657.9 to 61078.3) | 19119.4 (15249 to 23972.1) | 21377.9 (16900.1 to 27042.2) | |
| Anti-HPV-18, Month 7 (N=92,95,93) | 23228 (18677 to 28887.8) | 4709.9 (3604.2 to 6154.9) | 8009.4 (6111.1 to 10497.4) | |
| Anti-HPV-16, Month 12 (N=90,93,91) | 10635.3 (8555.9 to 13220) | 3959.4 (3039.1 to 5158.4) | 5858.1 (4610.9 to 7442.8) | |
| Anti-HPV-18, Month 12 (N=90,93,91) | 3651.5 (2903.6 to 4592.1) | 656.3 (493.6 to 872.6) | 1734.2 (1268.4 to 2371) | |
| Anti-HPV-16, Month 18 (N=90,92,91) | 8388.4 (6647.7 to 10584.9) | 1953.5 (1386.6 to 2752.3) | 2988.9 (2227.2 to 4011.2) | |
| Anti-HPV-18, Month 18 (N=89,92,92) | 2381.1 (1858.7 to 3050.2) | 283.1 (209.4 to 382.7) | 805.7 (574.4 to 1130.2) | |

Statistical analyses

No statistical analyses for this end point

Secondary: T-cell-mediated immune responses in the sub-cohort for CMI

| | |
|-----------------|--|
| End point title | T-cell-mediated immune responses in the sub-cohort for CMI |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 0 and Months 7, 12

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|--|--------------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 71 | 68 | 70 | |
| Units: T-cells/million cells | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| CD4+ All doubles, Anti-HPV-16, Day 0 (N=57,47,55) | 14 (1 to 97) | 22 (1 to 73) | 33 (1 to 80) | |
| CD4+ All doubles, Anti-HPV-18, Day 0 (N=57,46,56) | 20 (1 to 83) | 19 (1 to 101) | 24 (1 to 91.5) | |
| CD4+ All doubles, Anti-HPV-16, Month 7(N=68,63,65) | 1604.5 (634.5 to 3253.5) | 853 (429 to 1324) | 1131 (694 to 1969) | |
| CD4+ All doubles, Anti-HPV-18, Month 7(N=67,63,66) | 897 (522 to 2497) | 459 (240 to 761) | 654.5 (384 to 1284) | |
| CD4+ All doubles, Anti-HPV-16, Month12(N=71,66,70) | 1121 (659 to 2340) | 622.5 (316 to 1261) | 844.5 (546 to 1652) | |
| CD4+ All doubles, Anti-HPV-18, Month12(N=71,68,70) | 789 (400 to 1492) | 355 (209 to 673.5) | 465.5 (205 to 901) | |
| CD4-d-CD40L, Anti-HPV-16,Day 0 (N=57,47,55) | 10 (1 to 78) | 14 (1 to 73) | 30 (1 to 80) | |
| CD4-d-CD40L, Anti-HPV-18,Day 0 (N=57,46,56) | 14 (1 to 83) | 27 (1 to 101) | 25.5 (1 to 68.5) | |
| CD4-d-CD40L, Anti-HPV-16,Month 7(N=68,63,65) | 1507.5 (631.5 to 3043) | 779 (426 to 1219) | 1054 (670 to 1938) | |
| CD4-d-CD40L, Anti-HPV-18,Month7 (N=67,63,66) | 866 (509 to 2379) | 418 (227 to 775) | 616.5 (344 to 1193) | |
| CD4-d-CD40L, Anti-HPV-16,Month 12(N=71,66,70) | 990 (594 to 2236) | 592.5 (280 to 1135) | 805 (469 to 1545) | |
| CD4-d-CD40L, Anti-HPV-18,Month 12(N=71,68,70) | 688 (346 to 1435) | 340.5 (168 to 604.5) | 404 (219 to 737) | |

Statistical analyses

No statistical analyses for this end point

Secondary: T-cell-mediated immune responses in the sub-cohort for CMI

| | |
|-----------------|--|
| End point title | T-cell-mediated immune responses in the sub-cohort for CMI |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 0 and Months 7, 12

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|--|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 71 | 68 | 70 | |
| Units: T cells/million cells | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| CD4-d- IFN γ , Anti-HPV-16,Day 0 (N=57,47,55) | 1 (1 to 30) | 14 (1 to 42) | 1 (1 to 28) | |
| CD4-d- IFN γ , Anti-HPV-18,Day 0(N=57,46,56) | 14 (1 to 32) | 7 (1 to 35) | 1.5 (1 to 31.5) | |
| CD4-d- IFN γ , Anti-HPV-16,Month 7(N=68,63,65) | 351 (164.5 to 829) | 314 (141 to 602) | 398 (193 to 708) | |
| CD4-d- IFN γ , Anti-HPV-18,Month 7(N=67,63,66) | 218 (108 to 631) | 127 (70 to 247) | 181.5 (70 to 371) | |
| CD4-d- IFN γ , Anti-HPV-16,Month 12(N=71,66,70) | 326 (110 to 688) | 241.5 (86 to 606) | 337 (135 to 734) | |
| CD4-d- IFN γ , Anti-HPV-18,Month 12(N=71,68,70) | 174 (87 to 444) | 114 (56.5 to 259.5) | 155.5 (56 to 315) | |
| CD4-d-IL-2, Anti-HPV-16,Day 0 (N=57,47,55) | 16 (1 to 71) | 24 (1 to 68) | 33 (1 to 58) | |
| CD4-d-IL-2, Anti-HPV-18, Day 0 (N=57,46,56) | 1 (1 to 42) | 30 (1 to 66) | 20 (1 to 58) | |
| CD4-d-IL-2, Anti-HPV-16,Month 7(N=68,63,65) | 1323 (537 to 2702.5) | 710 (368 to 1058) | 875 (580 to 1431) | |
| CD4-d-IL-2, Anti-HPV-18,Month 7(N=67,63,66) | 737 (420 to 2185) | 321 (206 to 573) | 503 (295 to 869) | |
| CD4-d-IL-2, Anti-HPV-16,Month 12(N=71,66,70) | 922 (528 to 2050) | 487.5 (285 to 991) | 702.5 (450 to 1379) | |
| CD4-d-IL-2, Anti-HPV-18,Month 12(N=71,68,70) | 620 (311 to 1157) | 274 (164.5 to 550.5) | 380 (160 to 705) | |

Statistical analyses

No statistical analyses for this end point

Secondary: T-cell-mediated immune responses in the sub-cohort for CMI

| | |
|-----------------|--|
| End point title | T-cell-mediated immune responses in the sub-cohort for CMI |
|-----------------|--|

End point description:

| | |
|---------------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| At Day 0 and Months 7, 12 | |

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|--|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 71 | 68 | 70 | |
| Units: T cells/million cells | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| CD4-d-TNFα, Anti-HPV-16,Day 0 (N=57,47,55) | 6 (1 to 52) | 32 (1 to 73) | 16 (1 to 71) | |
| CD4-d-TNFα, Anti-HPV-18,Day 0 (N=57,46,56) | 24 (1 to 73) | 19 (1 to 82) | 21 (1 to 57) | |
| CD4-d-TNFα, Anti-HPV-16,Month 7(N=68,63,65) | 1103 (432 to 2399) | 605 (276 to 919) | 804 (458 to 1512) | |
| CD4-d-TNFα, Anti-HPV-18,Month 7(N=67,63,66) | 647 (371 to 1765) | 319 (153 to 594) | 517 (272 to 978) | |
| CD4-d-TNFα, Anti-HPV-16,Month 12(N=71,66,70) | 884 (488 to 1924) | 527 (210 to 1033) | 725 (383 to 1445) | |
| CD4-d-TNFα, Anti-HPV-18,Month 12(N=71,68,70) | 674 (290 to 1272) | 299 (144.5 to 600) | 403 (175 to 771) | |

Statistical analyses

No statistical analyses for this end point

Secondary: T-cell-mediated immune responses in the sub-cohort for CMI

| | |
|---------------------------|--|
| End point title | T-cell-mediated immune responses in the sub-cohort for CMI |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| At Day 0 and Months 7, 12 | |

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|--|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 71 | 68 | 70 | |
| Units: T cells/million cells | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| CD8-ALL DOUBLES, Anti-HPV-16, Day 0 (N=57,47,55) | 1 (1 to 14) | 2 (1 to 43) | 1 (1 to 32) | |
| CD8-ALL DOUBLES, Anti-HPV-18, Day 0 (N=57,46,56) | 1 (1 to 10) | 1 (1 to 29) | 1 (1 to 23.5) | |
| CD8-ALL DOUBLES, Anti-HPV-16,Month 7(N=68,63,65) | 1 (1 to 33) | 1 (1 to 40) | 1 (1 to 33) | |

| | | | | |
|---|-------------|---------------|-------------|--|
| CD8-ALL DOUBLES, Anti-HPV-18,Month 7(N=67,63,66) | 1 (1 to 19) | 1 (1 to 37) | 1 (1 to 40) | |
| CD8-ALL DOUBLES, Anti-HPV-16,Month 12(N=71,66,70) | 1 (1 to 31) | 1 (1 to 44) | 1 (1 to 32) | |
| CD8-ALL DOUBLES, Anti-HPV-18,Month 12(N=71,68,70) | 1 (1 to 27) | 1 (1 to 32.5) | 1 (1 to 20) | |
| CD8-d-CD40L, Anti-HPV-16, Day 0 (N=57,47,55) | 1 (1 to 1) | 1 (1 to 3) | 1 (1 to 1) | |
| CD8-d-CD40L, Anti-HPV-18, Day 0 (N=57,46,56) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 1) | |
| CD8-d-CD40L, Anti-HPV-16,Month 7(N=68,63,65) | 1 (1 to 1) | 1 (1 to 28) | 1 (1 to 24) | |
| CD8-d-CD40L, Anti-HPV-18,Month 7(N=67,63,66) | 1 (1 to 1) | 1 (1 to 24) | 1 (1 to 20) | |
| CD8-d-CD40L, Anti-HPV-16,Month 12(N=71,66,70) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 3) | |
| CD8-d-CD40L, Anti-HPV-18,Month 12(N=71,68,70) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 1) | |

Statistical analyses

No statistical analyses for this end point

Secondary: T-cell-mediated immune responses in the sub-cohort for CMI

| | |
|---------------------------|--|
| End point title | T-cell-mediated immune responses in the sub-cohort for CMI |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| At Day 0 and Months 7, 12 | |

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|---|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 71 | 68 | 70 | |
| Units: T cells/ million cells | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| CD8-d-IFN γ , Anti-HPV-16, Day 0 (N=57,47,55) | 1 (1 to 1) | 1 (1 to 36) | 1 (1 to 30) | |
| CD8-d-IFN γ , Anti-HPV-18, Day 0 (N=57,46,56) | 1 (1 to 2) | 1 (1 to 24) | 1 (1 to 14) | |
| CD8-d-IFN γ , Anti-HPV-16,Month 7(N=68,63,65) | 1 (1 to 31) | 1 (1 to 36) | 1 (1 to 30) | |
| CD8-d-IFN γ , Anti-HPV-18,Month 7(N=67,63,66) | 1 (1 to 1) | 1 (1 to 27) | 1 (1 to 28) | |
| CD8-d-IFN γ , Anti-HPV-16,Month 12(N=71,66,70) | 1 (1 to 28) | 1 (1 to 29) | 1 (1 to 28) | |
| CD8-d-IFN γ , Anti-HPV-18, Month 12 (N=71,68,70) | 1 (1 to 26) | 1 (1 to 32.5) | 1 (1 to 10) | |
| CD8-d-IL-2, Anti-HPV-16, Day 0 (N=57,47,55) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 1) | |

| | | | | |
|---|------------|------------|------------|--|
| CD8-d-IL-2, Anti-HPV-18,Day 0 (N=57,46,56) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 1) | |
| CD8-d-IL-2, Anti-HPV-16,Month 7(N=68,63,65) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 1) | |
| CD8-d-IL-2, Anti-HPV-18,Month 7(N=67,63,66) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 1) | |
| CD8-d-IL-2, Anti-HPV-16,Month 12(N=71,66,70) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 1) | |
| CD8-d-IL-2, Anti-HPV-18,Month 12(N=71,68,70) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 1) | |

Statistical analyses

No statistical analyses for this end point

Secondary: T-cell-mediated immune responses in the sub-cohort for CMI

| | |
|-----------------|--|
| End point title | T-cell-mediated immune responses in the sub-cohort for CMI |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 0 and Months 7, 12

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|---|--------------------------|--------------------------|--------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 71 | 68 | 70 | |
| Units: T cells/million cells | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| CD8-d-TNFα, Anti-HPV-16, Day 0 (N=57,47,55) | 1 (1 to 1) | 1 (1 to 36) | 1 (1 to 22) | |
| CD8-d-TNFα, Anti-HPV-18, Day 0 (N=57,46,56) | 1 (1 to 25) | 1 (1 to 30) | 1 (1 to 13.5) | |
| CD8-d-TNFα, Anti-HPV-16,Month 7(N=68,63,65) | 1 (1 to 26) | 1 (1 to 25) | 1 (1 to 22) | |
| CD8-d-TNFα, Anti-HPV-18,Month 7(N=67,63,66) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 23) | |
| CD8-d-TNFα, Anti-HPV-16,Month 12(N=71,66,70) | 1 (1 to 1) | 1 (1 to 25) | 1 (1 to 29) | |
| CD8-d-TNFα, Anti-HPV-18,Month 12(N=71,68,70) | 1 (1 to 8) | 1 (1 to 21.5) | 1 (1 to 24) | |

Statistical analyses

No statistical analyses for this end point

Secondary: T-cell-mediated immune responses in the sub-cohort for CMI

| | |
|-----------------|--|
| End point title | T-cell-mediated immune responses in the sub-cohort for CMI |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Month 24

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|--|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 71 | 68 | 70 | |
| Units: T cells/million cells | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| CD4+ All doubles, Anti-HPV-16,Month 24(N=66,65,71) | 1097 (489 to 2410) | 738 (360 to 1109) | 974 (573 to 1838) | |
| CD4+ All doubles, Anti-HPV-18,Month 24(N=65,65,70) | 630 (301 to 1383) | 348 (202 to 549) | 561.5 (258 to 972) | |
| CD4-d-CD40L, Anti-HPV-16,Month 24(N=66,65,71) | 1083 (510 to 2269) | 734 (346 to 1084) | 964 (582 to 1802) | |
| CD4-d-CD40L, Anti-HPV-18,Month 24(N=65,65,70) | 587 (282 to 1344) | 333 (206 to 534) | 563.5 (289 to 940) | |
| CD4-d- IFN γ , Anti-HPV-16,Month 24(N=66,65,71) | 276 (111 to 781) | 315 (128 to 519) | 431 (157 to 777) | |
| CD4-d- IFN γ , Anti-HPV-18,Month 24(N=65,65,70) | 169 (59 to 440) | 106 (51 to 227) | 218 (63 to 362) | |
| CD4-d-IL-2, Anti-HPV-16,Month 24(N=66,65,71) | 879.5 (429 to 1711) | 574 (280 to 898) | 687 (479 to 1480) | |
| CD4-d-IL-2, Anti-HPV-18,Month 24(N=65,65,70) | 494 (238 to 926) | 248 (138 to 415) | 400.5 (206 to 713) | |
| CD4-d-TNF α , Anti-HPV-16,Month 24(N=66,65,71) | 755 (375 to 1668) | 524 (235 to 876) | 791 (416 to 1516) | |
| CD4-d-TNF α , Anti-HPV-18,Month 24(N=65,65,70) | 479 (183 to 1036) | 238 (130 to 478) | 519 (228 to 793) | |

Statistical analyses

No statistical analyses for this end point

Secondary: T-cell-mediated immune responses in the sub-cohort for CMI

| | |
|-----------------|--|
| End point title | T-cell-mediated immune responses in the sub-cohort for CMI |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Month 24

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|---|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 71 | 68 | 70 | |
| Units: T cells/million cells | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| CD8-ALL DOUBLES, Anti-HPV-16,Month 24(N=66,65,71) | 1 (1 to 29) | 1 (1 to 1) | 1 (1 to 2) | |
| CD8-ALL DOUBLES, Anti-HPV-18,Month 24(N=65,65,70) | 1 (1 to 30) | 1 (1 to 30) | 1 (1 to 31) | |
| CD8-d-CD40L, Anti-HPV-16,Month 24(N=66,65,71) | 1 (1 to 23) | 1 (1 to 1) | 1 (1 to 1) | |
| CD8-d-CD40L, Anti-HPV-18,Month 24(N=65,65,70) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 23) | |
| CD8-d-IFN γ , Anti-HPV-16,Month 24(N=66,65,71) | 1 (1 to 19) | 1 (1 to 1) | 1 (1 to 3) | |
| CD8-d-IFN γ , Anti-HPV-18,Month 24(N=65,65,70) | 1 (1 to 1) | 1 (1 to 23) | 1 (1 to 23) | |
| CD8-d-IL-2, Anti-HPV-16,Month 24(N=66,65,71) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 1) | |
| CD8-d-IL-2, Anti-HPV-18,Month 24(N=65,65,70) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 1) | |
| CD8-d-TNF α , Anti-HPV-16,Month 24(N=66,65,71) | 1 (1 to 27) | 1 (1 to 1) | 1 (1 to 1) | |
| CD8-d-TNF α , Anti-HPV-18,Month 24(N=65,65,70) | 1 (1 to 18) | 1 (1 to 23) | 1 (1 to 21) | |

Statistical analyses

No statistical analyses for this end point

Secondary: B-cell-mediated immune responses in the sub-cohort for CMI

| | |
|--|--|
| End point title | B-cell-mediated immune responses in the sub-cohort for CMI |
| End point description: | |
| The frequency of B-cell Elispot response to HPV-16/18 by overall status was presented. At the time of posting this record, the results for Month 36 were not available. The record will be updated when the additional validated results are available | |
| End point type | Secondary |
| End point timeframe: | |
| At Day 0 and Months 7, 12, 24 and 36 | |

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|---------------------------------------|--------------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 76 | 72 | 80 | |
| Units: B cells/million cells | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| HPV-16, PRE (N=74,59,73) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | |
| HPV-18, PRE (N=74,59,73) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | |
| HPV-16, M7 (N=76,72,80) | 1605.5 (593.5 to 3483.5) | 1097.5 (449 to 2068) | 687 (115.5 to 1966.5) | |

| | | | | |
|--------------------------|-----------------------|-------------------|-----------------|--|
| HPV-18, M7 (N=76,72,80) | 593.5 (103.5 to 1771) | 80 (0 to 376) | 111 (0 to 391) | |
| HPV-16, M12 (N=56,56,57) | 396.5 (89 to 1044) | 248 (61.5 to 756) | 281 (47 to 974) | |
| HPV-18, M12 (N=56,56,57) | 252 (77 to 635) | 67 (0 to 182.5) | 65 (0 to 220) | |
| HPV-16, M24 (N=52,50,61) | 254.5 (13 to 706) | 204 (16 to 578) | 256 (68 to 600) | |
| HPV-18, M24 (N=52,50,61) | 125.5 (31 to 370.5) | 45 (0 to 143) | 110 (0 to 287) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with solicited local symptoms.

| | |
|---|---|
| End point title | Number of subjects with solicited local symptoms. |
| End point description: | |
| Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimetres (mm) of injection site. Relationship analysis was not performed. Note: Grade 3 symptoms are not presented since cases are still unblinded due to the study being ongoing. They will be added once results become available. | |
| End point type | Secondary |
| End point timeframe: | |
| During the 7-day period (Days 0-6) following vaccination (across doses) | |

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|-----------------------------|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 359 | 357 | 356 | |
| Units: Subjects | | | | |
| Any Pain | 329 | 276 | 295 | |
| Grade 3 Pain | 42 | 17 | 18 | |
| Any Redness | 191 | 134 | 157 | |
| Grade 3 Redness | 0 | 0 | 0 | |
| Any Swelling | 163 | 98 | 118 | |
| Grade 3 Swelling | 0 | 0 | 0 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with solicited general symptoms.

| | |
|--|---|
| End point title | Number of subjects with solicited general symptoms. |
| End point description: | |
| Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, | |

myalgia, rash, temperature [defined as oral temperature equal to or above 37.5 degrees Celsius (°C)] and urticaria. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Note: Grade 3 symptoms are not presented since cases are still unblinded due to the study being ongoing. They will be added once results become available.

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: | |
| During the 7-day period (Days 0-6) following vaccination (across doses) | |

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|-----------------------------|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 359 | 357 | 356 | |
| Units: Subjects | | | | |
| Any Arthralgia | 68 | 81 | 67 | |
| Grade 3 Arthralgia | 6 | 4 | 1 | |
| Related Arthralgia | 51 | 55 | 51 | |
| Any Fatigue | 192 | 199 | 193 | |
| Grade 3 Fatigue | 18 | 15 | 7 | |
| Related Fatigue | 151 | 151 | 143 | |
| Any Gastrointestinal | 55 | 74 | 69 | |
| Grade 3 Gastrointestinal | 5 | 6 | 3 | |
| Related Gastrointestinal | 31 | 49 | 40 | |
| Any Headache | 147 | 133 | 151 | |
| Grade 3 Headache | 17 | 7 | 4 | |
| Related Headache | 106 | 88 | 100 | |
| Any Myalgia | 166 | 143 | 136 | |
| Grade 3 Myalgia | 8 | 8 | 6 | |
| Related Myalgia | 128 | 111 | 100 | |
| Any Rash | 26 | 16 | 18 | |
| Grade 3 Rash | 0 | 0 | 0 | |
| Related Rash | 16 | 10 | 12 | |
| Any Temperature | 53 | 59 | 47 | |
| Grade 3 Temperature | 0 | 0 | 0 | |
| Related Temperature | 35 | 31 | 30 | |
| Any Urticaria | 27 | 13 | 25 | |
| Grade 3 Urticaria | 0 | 0 | 0 | |
| Related Urticaria | 15 | 11 | 9 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with unsolicited adverse events (AEs).

| | |
|--|---|
| End point title | Number of subjects with unsolicited adverse events (AEs). |
| End point description: | |
| An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal | |

product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: | |
| During the 30-day period (Days 0-29) post-vaccination | |

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|---------------------------------|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 359 | 358 | 358 | |
| Units: Subjects | | | | |
| Subjects with any AE(s) | 91 | 96 | 100 | |
| Subjects with any Grade 3 AE(s) | 18 | 8 | 20 | |
| Subjects with any Related AE(s) | 8 | 13 | 16 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with potentially immune mediated diseases (pIMDs)

| | |
|---|--|
| End point title | Number of subjects with potentially immune mediated diseases (pIMDs) |
| End point description: | |
| Note: Results beyond Month 24 will be updated when validated results become available | |
| End point type | Secondary |
| End point timeframe: | |
| From Day 0 to Month 36 (throughout the study period) | |

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|-------------------------------------|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 359 | 358 | 358 | |
| Units: Subjects | | | | |
| Subjects with any pIMD(s), Month 7 | 2 | 1 | 0 | |
| Subjects with any pIMD(s), Month 12 | 3 | 3 | 0 | |
| Subjects with any pIMD(s), Month 18 | 3 | 3 | 0 | |
| Subjects with any pIMD(s), Month 24 | 3 | 3 | 0 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with medically significant conditions (MSCs)

| | |
|-----------------|---|
| End point title | Number of subjects with medically significant conditions (MSCs) |
|-----------------|---|

End point description:

MSCs were defined as AEs prompting emergency room (ER) or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs not related to common diseases. Common diseases include: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury. Note: Results beyond Month 24 will be updated when validated results become available

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 0 to Month 36 (throughout the study period)

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|------------------------------------|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 359 | 358 | 358 | |
| Units: Subjects | | | | |
| Subjects with any MSC(s), Month 7 | 43 | 49 | 39 | |
| Subjects with any MSC(s), Month 12 | 52 | 57 | 47 | |
| Subjects with any MSC(s), Month 18 | 65 | 64 | 54 | |
| Subjects with any MSC(s), Month 24 | 71 | 75 | 56 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with Serious Adverse Events (SAEs)

| | |
|-----------------|---|
| End point title | Number of subjects with Serious Adverse Events (SAEs) |
|-----------------|---|

End point description:

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Note: SAEs were not listed as they remain blinded until the end of the study.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 0 to Month 36 (throughout the study period)

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|-----------------------------|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 359 ^[7] | 358 ^[8] | 358 ^[9] | |
| Units: Subjects | | | | |
| Any SAE(s) | 0 | 0 | 0 | |

Notes:

[7] - SAEs were not listed as they remain blinded until the end of the study.

[8] - SAEs were not listed as they remain blinded until the end of the study.

[9] - SAEs were not listed as they remain blinded until the end of the study.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects starting a concomitant medication

| | |
|-----------------|--|
| End point title | Number of subjects starting a concomitant medication |
|-----------------|--|

End point description:

The outcome presents the number of subjects starting any concomitant medication, as well as any antipyretic, any prophylactic antipyretic and any antibiotic. Note: The number of subjects starting any prophylactic antipyretic is blinded at the time of posting this record. The record will be updated once it becomes available.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 30-day (Days 0-29) post-vaccination period

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|-----------------------------|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 359 | 358 | 358 | |
| Units: Subjects | | | | |
| Any concomitant medication | 127 | 127 | 129 | |
| Any antipyretic | 68 | 74 | 71 | |
| Any antibiotic | 23 | 27 | 32 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects starting a concomitant medication

| | |
|-----------------|--|
| End point title | Number of subjects starting a concomitant medication |
|-----------------|--|

End point description:

The outcome presents the number of subjects starting any concomitant medication, as well as any antipyretic, any prophylactic antipyretic and any antibiotic. Note: The number of subjects starting any prophylactic antipyretic is blinded at the time of posting this record. The record will be updated once it becomes available. Results for timepoints beyond Month 24 will be added once they become available.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 0 to Month 36 (throughout the study period)

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|---|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 359 | 358 | 354 | |
| Units: Subjects | | | | |
| Any antipyretic, M7 [N=359,358,354] | 68 | 74 | 71 | |
| Any concomitant medication, M7 [N=359,358,354] | 127 | 127 | 129 | |
| Any antibiotic, M7 [N=359,358,354] | 23 | 27 | 32 | |
| Any concomitant medication, M12 [N=356,348,350] | 158 | 138 | 153 | |
| Any antipyretic, M12 [N=356,348,350] | 90 | 80 | 81 | |
| Any antibiotic, M12 [N=356,348,350] | 37 | 33 | 43 | |
| Any concomitant medication, M18 [N=356,347,349] | 158 | 138 | 153 | |
| Any antipyretic, M18 [N=356,347,349] | 90 | 80 | 81 | |
| Any antibiotic, M18 [N=356,347,349] | 37 | 33 | 43 | |
| Prophylactic antipyretic, M12 [N=356,348,350] | 5 | 2 | 2 | |
| Prophylactic antipyretic, M18 [N=356,347,349] | 5 | 2 | 2 | |
| Any concomitant medication, M24 [N=355,344,349] | 163 | 146 | 157 | |
| Any antipyretic, M24 [N=355,344,349] | 94 | 82 | 80 | |
| Prophylactic antipyretic, M24 [N=356,347,349] | 5 | 2 | 2 | |
| Any antibiotic, M24 [N=355,344,349] | 43 | 38 | 46 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects completing the vaccination schedule

| | |
|---|--|
| End point title | Number of subjects completing the vaccination schedule |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| Throughout the study period (From Day 0 up to Month 36) | |

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|--|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 359 | 358 | 358 | |
| Units: Subjects | | | | |
| Subjects receiving all 3 vaccine doses | 357 | 352 | 354 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with pregnancies

| | |
|-----------------|-------------------------------------|
| End point title | Number of subjects with pregnancies |
|-----------------|-------------------------------------|

End point description:

Note: No pregnancies were reported up to the Month 12 time point. Results beyond Month 24 will be updated when validated results become available

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Throughout the study period (From Day 0 up to Month 36)

| End point values | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group | |
|----------------------------------|-----------------------|-----------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 359 | 358 | 358 | |
| Units: Subjects | | | | |
| Subjects with any pregnancy, M12 | 0 | 0 | 0 | |
| Subjects with any pregnancy, M18 | 0 | 0 | 0 | |
| Subject with any pregnancy, M24 | 0 | 0 | 0 | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited symptoms: up to Day 7 post vaccination. AEs: up to Day 30 post vaccination. SAEs throughout the study period (up to Month 36).

Adverse event reporting additional description:

SAEs were not listed as they remain blinded until the end of the study.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 18.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-----------------------|
| Reporting group title | Cervarix 2 dose Group |
|-----------------------|-----------------------|

Reporting group description:

Subjects who received 2 doses of Cervarix™ vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.

| | |
|-----------------------|-----------------------|
| Reporting group title | Gardasil 2 dose Group |
|-----------------------|-----------------------|

Reporting group description:

Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.

| | |
|-----------------------|-----------------------|
| Reporting group title | Gardasil 3 dose Group |
|-----------------------|-----------------------|

Reporting group description:

Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.

| Serious adverse events | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group |
|---|-----------------------|-----------------------|-----------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 359 (0.00%) | 0 / 358 (0.00%) | 0 / 358 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Cervarix 2 dose Group | Gardasil 2 dose Group | Gardasil 3 dose Group |
|---|-----------------------|-----------------------|-----------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 329 / 359 (91.64%) | 276 / 358 (77.09%) | 295 / 358 (82.40%) |
| General disorders and administration site conditions | | | |

| | | | |
|-----------------------------------|--------------------|--------------------|--------------------|
| Pain | | | |
| subjects affected / exposed | 329 / 359 (91.64%) | 276 / 358 (77.09%) | 295 / 358 (82.40%) |
| occurrences (all) | 329 | 276 | 295 |
| Redness | | | |
| subjects affected / exposed | 191 / 359 (53.20%) | 134 / 358 (37.43%) | 157 / 358 (43.85%) |
| occurrences (all) | 191 | 134 | 157 |
| Swelling | | | |
| subjects affected / exposed | 163 / 359 (45.40%) | 98 / 358 (27.37%) | 118 / 358 (32.96%) |
| occurrences (all) | 163 | 98 | 118 |
| Arthralgia | | | |
| subjects affected / exposed | 68 / 359 (18.94%) | 81 / 358 (22.63%) | 67 / 358 (18.72%) |
| occurrences (all) | 68 | 81 | 67 |
| Fatigue | | | |
| subjects affected / exposed | 192 / 359 (53.48%) | 199 / 358 (55.59%) | 193 / 358 (53.91%) |
| occurrences (all) | 192 | 199 | 193 |
| Gastrointestinal | | | |
| subjects affected / exposed | 55 / 359 (15.32%) | 74 / 358 (20.67%) | 69 / 358 (19.27%) |
| occurrences (all) | 55 | 74 | 69 |
| Headache | | | |
| subjects affected / exposed | 147 / 359 (40.95%) | 133 / 358 (37.15%) | 151 / 358 (42.18%) |
| occurrences (all) | 147 | 133 | 151 |
| Myalgia | | | |
| subjects affected / exposed | 166 / 359 (46.24%) | 143 / 358 (39.94%) | 136 / 358 (37.99%) |
| occurrences (all) | 166 | 143 | 136 |
| Rash | | | |
| subjects affected / exposed | 26 / 359 (7.24%) | 16 / 358 (4.47%) | 18 / 358 (5.03%) |
| occurrences (all) | 26 | 16 | 18 |
| Temperature | | | |
| subjects affected / exposed | 53 / 359 (14.76%) | 59 / 358 (16.48%) | 47 / 358 (13.13%) |
| occurrences (all) | 53 | 59 | 47 |
| Urticaria | | | |
| subjects affected / exposed | 27 / 359 (7.52%) | 13 / 358 (3.63%) | 25 / 358 (6.98%) |
| occurrences (all) | 27 | 13 | 25 |
| Infections and infestations | | | |
| Upper respiratory tract infection | | | |

| | | | |
|-----------------------------|------------------|------------------|------------------|
| subjects affected / exposed | 27 / 359 (7.52%) | 29 / 358 (8.10%) | 31 / 358 (8.66%) |
| occurrences (all) | 27 | 29 | 31 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 8 / 359 (2.23%) | 11 / 358 (3.07%) | 20 / 358 (5.59%) |
| occurrences (all) | 8 | 11 | 20 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|--------------|--|
| 02 July 2012 | Amendment 1 At the European Medicines Agency's (EMA) request, GSK Biologicals has updated its procedure for emergency unblinding during the conduct of a clinical study. According to the revised procedure, the responsibility and the decision to break the treatment code in emergency situations resides solely with the investigator and consequently, the investigator will have full authority to break the treatment code |
| 24 June 2014 | Amendment 3 At the time of study initiation, Cervarix was approved to be administered according to a 3-dose vaccination schedule. Subjects belonging to the study groups HPV_2D and Gard_2D received two doses of either Cervarix or Gardasil during the primary study epoch. These subjects were to be offered a third dose of the vaccine that they received, at the end of the study, at Month 36. Recently, the 2-dose schedule of Cervarix and Gardasil has been approved in some countries, and hence the protocol is being amended to reflect that a third dose of the vaccine that they received will be offered to the subjects in the two 2-dose groups (HPV_2D and Gard_2D) only if required based on local prescribing recommendations. In addition, the indication for Cervarix and the list of contributing authors have been updated. The number of countries in which Cervarix and Gardasil are licensed has been updated. Minor changes have been made in a few sections to correct typographical errors. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported